Free Trial
Steve Scala

Steve Scala Analyst Performance

Senior Research Analyst at TD Cowen

Steve Scala is a stock analyst at TD Cowen focused in the medical sector, covering 13 publicly traded companies. Over the past year, Steve Scala has issued 3 stock ratings, including buy and hold recommendations. While full access to Steve Scala's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Steve Scala's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
46 Last 11 Years
Buy Recommendations
73.33% 33 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy73.3%33 ratings
Hold26.7%12 ratings
Sell0.0%0 ratings

Out of 45 total stock ratings issued by Steve Scala at TD Cowen, the majority (73.3%) have been Buy recommendations, followed by 26.7% Hold.

Exchange Coverage

ExchangePercentageCount
NYSE
76.9% of companies on NYSE
10 companies
NASDAQ
15.4% of companies on NASDAQ
2 companies
OTCMKTS
7.7% of companies on OTCMKTS
1 company

Steve Scala, an analyst at TD Cowen, currently covers 13 companies listed on NYSE, NASDAQ and OTCMKTS, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
92.3%
Manufacturing
1 company
7.7%

Steve Scala of TD Cowen specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
8 companies
61.5%
MED - BIOMED/GENE
3 companies
23.1%
Miscellaneous
1 company
7.7%
MED - DRUGS
1 company
7.7%

About Steve Scala

Steve Scala is a senior research analyst with more than 30 years of experience following the pharmaceutical industry, including large-, mid- and small-cap companies. Prior to joining TD Cowen, Mr. Scala was a pharmacist at Tufts Medical Center in Boston. He received a BS in pharmacy from the University of Connecticut, an MS in pharmacy from Ohio State University, and an MBA from Bentley College. He is a CFA charterholder.
Follow on LinkedIn

Steve Scala's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
2/27/2026Reiterated Rating$46.20Buy
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1/20/2026Boost Price Target$108.76$120.00Hold
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
12/11/2025Boost Price Target$38.21$45.00Buy